Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Trials
Published in: Trials 1/2017

Open Access 01-12-2017 | Study protocol

A randomized phase II study to assess the effect of adjuvant immunotherapy using α-GalCer-pulsed dendritic cells in the patients with completely resected stage II–IIIA non-small cell lung cancer: study protocol for a randomized controlled trial

Authors: Hideo Saka, Chiyoe Kitagawa, Yukito Ichinose, Mitsuhiro Takenoyama, Hidenori Ibata, Tatsuo Kato, Koji Takami, Motohiro Yamashita, Tadashi Maeda, Sadanori Takeo, Hitoshi Ueda, Kan Okabayashi, Seiji Nagashima, Tadayuki Oka, Hidenori Kouso, Seiichi Fukuyama, Kentaro Yoshimoto, Mototsugu Shimokawa, Akiko M. Saito, Suminobu Ito

Published in: Trials | Issue 1/2017

Login to get access

Abstract

Background

As the toxicity associated with the α-GalCer-pulsed dendritic cell (DC) therapy could be considered to be negligible, its addition to postoperative adjuvant chemotherapy would be expected to greatly improve the therapeutic effect, and could result in prolonged survival.
The aim of the present study is to compare the therapeutic efficacy of alpha-galactosylceramide-pulsed DC therapy in patients who have undergone a complete resection of stage II–IIIA non-small-cell lung cancer (NSCLC) followed by postoperative adjuvant therapy with cisplatin plus vinorelbine, to that in patients who did not receive additional treatment (surgical resection plus postoperative adjuvant chemotherapy only).

Methods

Subsequent to the complete resection of NSCLC, followed by the administration of cisplatin plus vinorelbine dual-agent combination adjuvant chemotherapy, patients who satisfy the inclusion criteria will be randomly allocated to either the α-GalCer-pulsed DC immune therapy group, or the standard treatment group.
In total, 56 patients will be included in the study. The primary endpoint is recurrence-free survival, and the secondary endpoints are natural killer T-cell-specific immune response, the frequency of toxic effects and safety, and overall survival.

Discussion

In order to determine the efficacy of α-GalCer-pulsed DC therapy, the present study compares patients with stage II–III NSCLC who underwent complete surgical resection followed by postoperative adjuvant therapy with cisplatin plus vinorelbine, to those who did not receive additional treatment (surgical resection plus postoperative adjuvant chemotherapy only).

Trial registration

UMIN000010386 (R000012145). Registered on 1 April 2013.
UMIN-CTR is officially recognized as a registration site which satisfies ICMJE criteria.
Appendix
Available only for authorised users
Literature
1.
The International Adjuvant Lung Cancer Trial Collaborative Group. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med. 2004;350:351–60 [PubMed].CrossRef
2.
Winton T, Livingston R, Johnson D, et al. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med. 2005;352:2589–97 [PubMed].CrossRefPubMed
3.
Douillard JY, Rosell R, Lena D, et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small cell lung cancer (Adjuvant Navelbine International Trialists Association [ANITA]) a randomized control trial. Lancet Oncol. 2006;7:719–27 [PubMed].CrossRefPubMed
4.
Arriagada R, Dunant A, Pignon JP, et al. Long-term results of the international adjuvant lung cancer trial evaluating adjuvant cisplatin-based chemotherapy in resected lung cancer. J Clin Oncol. 2010;28:35–42 [PubMed].CrossRefPubMed
5.
Scagliotti GV, Fossati R, Torri V, et al. Adjuvant Lung Project Italy/European Organisation for Research Treatment of Cancer-Lung Cancer Cooperative Group Investigators. Randomized study of adjuvant chemotherapy for completely resected stage I, II, or IIIA non-small-cell lung cancer. J Natl Cancer Inst. 2003;95:1453–61 [PubMed].CrossRefPubMed
6.
Waller D, Stephens RJ, Milroy GR, et al. Chemotherapy for patients with non-small cell lung cancer: the surgical setting of the Big Lung Trial. Eur J Cardiothorac Surg. 2004;26:173–82 [PubMed].CrossRefPubMed
7.
Pignon JP, Tribodet H, Scagliotti GV, et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol. 2008;26:3552–9 [PubMed].CrossRefPubMed
8.
Douillard JY, Tribodet H, Aubert D, et al. Adjuvant cisplatin and vinorelbine for completely resected non-small cell lung cancer: subgroup analysis of the lung adjuvant cisplatin evaluation. J Thorac Oncol. 2010;5:220–8 [PubMed].CrossRefPubMed
9.
Taniguchi M, Harada M, et al. The regulatory role of Va14 NKT cells in innate and acquired immune response. Annu Rev Immunol. 2003;21:483–513 [PubMed].CrossRefPubMed
10.
Kawano T, Cui J, et al. CD1d-restricted and TCR-mediated activation of Va14 NKT cells by glycosylceramides. Science. 1997;278:1626–9 [PubMed].CrossRefPubMed
11.
Kawano T, Cui J, et al. Natural killer-like nonspecific tumor cell lysis mediated by specific ligand-activated Va14 NKT cells. Proc Natl Acad Sci U S A. 1998;95:5690–3 [PubMed].CrossRefPubMedPubMedCentral
12.
Taniguchi M, Seino K, et al. The NKT cell system: bridging innate and acquired immunity. Nat Immunol. 2003;4:1164–5 [PubMed].CrossRefPubMed
13.
Fujii S, Motohashi S, et al. Adjuvant activity mediated by iNKT cells. Semin Immunol. 2010;22:97–102 [PubMed].CrossRefPubMed
14.
Akutsu Y, Nakayama T, et al. Expansion of lung Va14 NKT cells by administration of a-galactosylceramide-pulsed dendritic cells. Jpn J Cancer Res. 2002;93:397–403 [PubMed].CrossRefPubMed
15.
Motohashi S, Kobayashi S, et al. Preserved IFN-g production of circulating Va24 NKT cells in primary lung cancer patients. Int J Cancer. 2002;102:159–65 [PubMed].CrossRefPubMed
16.
Toura I, Kawano T, et al. Cutting edge: inhibition of experimental tumor metastasis by dendritic cells pulsed with a-galactosylceramide. J Immunol. 1999;163:2387–91 [PubMed].PubMed
17.
Fujii S, Shimizu K, et al. Prolonged IFN-g-producing NKT response induced with a-galactosylceramide-loaded DCs. Nat Immunol. 2002;3:867–74 [PubMed].CrossRefPubMed
18.
Ishikawa A, Motohashi S, et al. A phase I study of a-galactosylceramide (KRN7000)-pulsed dendritic cells in patients with advanced and recurrent non-small cell lung cancer. Clin Cancer Res. 2005;11:1910–7 [PubMed].CrossRefPubMed
19.
Motohashi S, Nagato K, et al. A phase I-II study of a-galactosylceramide-pulsed IL-2/GM-CSF-cultured peripheral blood mononuclear cells in patients with advanced and recurrent non-small cell lung cancer. J Immunol. 2009;182:2492–501 [PubMed].CrossRefPubMed
Metadata
Title
A randomized phase II study to assess the effect of adjuvant immunotherapy using α-GalCer-pulsed dendritic cells in the patients with completely resected stage II–IIIA non-small cell lung cancer: study protocol for a randomized controlled trial
Authors
Hideo Saka
Chiyoe Kitagawa
Yukito Ichinose
Mitsuhiro Takenoyama
Hidenori Ibata
Tatsuo Kato
Koji Takami
Motohiro Yamashita
Tadashi Maeda
Sadanori Takeo
Hitoshi Ueda
Kan Okabayashi
Seiji Nagashima
Tadayuki Oka
Hidenori Kouso
Seiichi Fukuyama
Kentaro Yoshimoto
Mototsugu Shimokawa
Akiko M. Saito
Suminobu Ito
Publication date
01-12-2017
Publisher
BioMed Central
Published in
Trials / Issue 1/2017
Electronic ISSN: 1745-6215
DOI
https://doi.org/10.1186/s13063-017-2103-4

Other articles of this Issue 1/2017

Trials 1/2017 Go to the issue

Commentary

Health research participants are not receiving research results: a collaborative solution is needed

Study protocol

REstricted Fluid REsuscitation in Sepsis-associated Hypotension (REFRESH): study protocol for a pilot randomised controlled trial

Study protocol

The effects of Cognitive Bias Modification training and oxytocin administration on trust in maternal support: study protocol for a randomized controlled trial

Erratum

Erratum to: Medicine in spine exercise (MiSpEx) for nonspecific low back pain patients: study protocol for a multicentre, single-blind randomized controlled trial

Methodology

Simulating therapeutic drug monitoring results for dose individualisation to maintain investigator blinding in a randomised controlled trial

Study protocol

A coordinated PCP-Cardiologist Telemedicine Model (PCTM) in China’s community hypertension care: study protocol for a randomized controlled trial